Medical Condition News

RSS

Researchers discover how tamoxifen-resistant breast-cancer cells grow and proliferate

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

31 Oct 2012

Oily fish consumption may reduce risk of stroke

Eating at least two servings of oily fish a week is moderately but significantly associated with a reduced risk of stroke, finds a study published on bmj.com today.

31 Oct 2012

High vitamin D levels associated with protection against bladder cancer

High levels of vitamin D are associated with protection against bladder cancer, according to a multidisciplinary study coordinated by molecular biologists and epidemiologists from the Spanish National Cancer Research Centre (CNIO), the conclusions of which are being published today in the Journal of National Cancer Institute (JNCI) .

31 Oct 2012

More than one third of U.S. cancer survivors report poor physical or mental health

Beating cancer is just the first step. More than one third of the 12.6 million cancer survivors in the United States have physical or mental problems that put their overall health in jeopardy, according to researchers at Wake Forest Baptist Medical Center.

31 Oct 2012

Empathetic and analytic thinking mutually exclusive in the brain

New research shows a simple reason why even the most intelligent, complex brains can be taken by a swindler's story - one that upon a second look offers clues it was false.

31 Oct 2012

Childhood bullying can lead to long term health consequences

Childhood bullying can lead to long term health consequences, including general and mental health issues, behavioral problems, eating disorders, smoking, alcohol use, and homelessness, a study by the Crime Victims' Institute at Sam Houston State University found.

31 Oct 2012

Blocking RSK protein activity could improve treatment of skin cancers

Blocking the action of a particular protein in our skin could improve the treatment of skin cancers, according to a study published in Oncogene yesterday by Philippe Roux, a researcher at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC).

31 Oct 2012

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Fifty world-renowned experts in non-Hodgkins lymphoma will convene in New York in November to present the latest scientific and clinical advances in treating a "lost generation" of sufferers-children, young adults and adolescents.

31 Oct 2012

Study finds that just 1 high-fat meal can affect your heart health

Eat a breakfast sandwich and your body will be feeling the ill effects well before lunch - now that's fast food!

31 Oct 2012

Bronchial thermoplasty helps control severe asthma

Nearly 24 million people in this country suffer from asthma. For most of them, avoiding allergens and taking medications help keep their asthma under control. But for a small group with severe persistent asthma, frequent hospital visits tend to be the norm and taking medications and lifestyle changes don't do the trick. Northwestern Memorial Hospital is now using a new procedure called bronchial thermoplasty (BT), the first non-drug therapy approved by the Federal Drug Administration, for patients with severe asthma.

31 Oct 2012

Diffusion tensor imaging detects complex muscle structures in 3D

Eindhoven University of Technology (TU/e) and the Academic Medical Center (AMC) in Amsterdam have together developed a technique that allows detailed 3D imaging of complex muscle structures of patients.

31 Oct 2012

Unique bond between SAP102 and GluN2B enables learning and memory

Two proteins have a unique bond that enables brain receptors essential to learning and memory to not only get and stay where they're needed, but to be hauled off when they aren't, researchers say.

31 Oct 2012

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Swedish specialty pharmaceutical company Orexo today communicated the start of the dose finding study for OX51 in patients undergoing prostate biopsy.

31 Oct 2012

Researchers show how ingesting too much silver can cause argyria

Researchers from Brown University have shown for the first time how ingesting too much silver can cause argyria, a rare condition in which patients' skin turns a striking shade of grayish blue.

31 Oct 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Breast cancer screening reduces deaths but overdiagnoses

An independent panel of experts has concluded that routine breast cancer screening results in a reduced risk of dying from breast cancer compared to when no screening takes place, but that screening also results in overdiagnosis, according to a Review published in The Lancet.

30 Oct 2012

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Oct 2012

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump system in patients with ascites caused by cancer (malignant ascites).

30 Oct 2012